Results 41 to 50 of about 2,265,539 (159)
International Journal of Nanomedicine, 2014 Yingna He,1 Linhua Zhang,2 Dunwan Zhu,2 Cunxian Song2 1Laboratory of Chinese Medicine Pharmacology, College of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, People’s Republic of China; 2Key Laboratory of Biomedical Material ...
He Y, Zhang L, Zhu D, Song C
doaj
The Prostate, Volume 85, Issue 6, Page 541-557, May 2025.ABSTRACT Background Metastatic castration resistance prostate cancer (mCRPC) is a challenging disease with a significant burden of mortality and morbidity. Most of the patients attain resistance to the available treatments, necessitating further novel therapies in this clinical setting.
Huseyin Besiroglu, Mustafa Kadihasanoglu
wiley +1 more source
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors [PDF]
Cancer Chemotherapy and Pharmacology, 2014 To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide.Patients with advanced, solid tumors, positive for LHRH receptor by immunohistochemistry (IHC ...
Hector Alila +9 more
openaire +2 more sources
The Prostate, Volume 85, Issue 7, Page 693-702, May 15, 2025.ABSTRACT Objective The Prognostic Nutritional Index (PNI), reflects the nutritional and immunological status of the patient and has been associated with outcomes in various cancers. In this study, the prognostic significance of PNI in metastatic hormone‐sensitive prostate cancer (mHSPC) and its potential role in guiding treatment decisions between ...
Muhammet Bekir Hacioglu +12 more
wiley +1 more source
Journal of Applied Clinical Medical Physics, Volume 26, Issue 4, April 2025.Abstract Background Various methods exist to correct for intrafraction motion (IFM) of the prostate during radiotherapy. We sought to characterize setup corrections in our practice informed by the TrueBeam Advanced imaging package, and analyze factors associated with IFM.
Lucas M. Serra +4 more
wiley +1 more source
, 1978 Treatment of adult male rats with the potent LHRH agonists [D-Leu6, des-Gly-NH210]LHRH ethylamide or [D-Ala6. des-Gly-NH210]LHRH ethylamide led to a marked reduction of testicular LH and prolactin receptor levels accompanied by decreased plasma ...
F. Labrie +5 more
semanticscholar +1 more source
Cancer Reports, Volume 8, Issue 4, April 2025.ABSTRACT Background Small bowel adenocarcinomas (SBAs) are rare and aggressive cancers. About one‐fifth of SBA patients have predisposing conditions; among them, there are also genetic tumor syndromes, including Lynch syndrome, familial adenomatous polyposis, and Peutz‐Jeghers syndrome.
Francesca Antoci +12 more
wiley +1 more source
WITHDRAWN: The use of nanoparticles in LHRH receptor targeted therapy for cancer
Experimental and Molecular Pathology, 2009 While chemotherapy remains the most effective means of treatment for cancer patients, it has become apparent that more efficient modalities are needed. As an alternative to current methods, which can often be toxic to healthy cells and tissues, we discuss "targeted therapy" as an alternate to conventional chemotherapy.
Sham S. Kakar, Sarah E. Norberto
openaire +3 more sources
A novel model of central precocious puberty disease: Paternal MKRN3 gene–modified rabbit
Animal Models and Experimental Medicine, Volume 8, Issue 3, Page 511-522, March 2025.This study found increased gonadotropin releasing hormone (GnRH) and decreased gonadotropin inhibiting hormone (GnIH) in the hypothalamus of the central precocious puberty (CPP) rabbit model with MKRN3 gene mutation. It is suggested that the CPP caused by mkrtn3 mutation may be related to the activation of the GnRH pathway and the inhibition of the ...
Bangzhu Chen +9 more
wiley +1 more source
Hormone Receptor Positive Breast Cancer in Young Women: A Review
Journal of Surgical Oncology, Volume 131, Issue 4, Page 580-586, March 15, 2025.ABSTRACT The global incidence of hormone‐positive breast cancer (HR+ BC) in young women is rising, though the underlying reasons remain unclear. HR+ disease in younger women appears to represent a distinct clinical entity compared to that in older women, exhibiting distinct clinicopathological characteristics, outcomes and responses to treatment ...
Nicola McShane +4 more
wiley +1 more source